Stockreport

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 [Yahoo! Finance]

OKYO Pharma Limited - American Depositary Shares  (OKYO) 
PDF innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neurop [Read more]